Monitoring & Maintenance Regular check-ins throughout the program
If oral semaglutide did not produce sufficient results, the superior bioavailability and dual-receptor mechanism of injectable tirzepatide may provide the additional efficacy needed
These situations benefit from in-person medical oversight with lab work and physical examinations that telehealth cannot replicate
Tirzepatide is a glucose-dependent insulinotropic polypeptide/GLP- 1 dual receptor agonist (GIP/GLP- 1 RA) and in the Phase 3 SURMOUNT- 1 trial, tirzepatide 5 mg, 10 mg and 15 mg produced mean weight reduction from baseline to week 72 of 15,0%, 18.5% and 20.9%, respectively, versus 2.4% for placebo
Losing weight is like knocking down a row of dominos
Acute effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on arcuate pro-opiomelanocortin (POMC) neurons